Page 11234..10..»

Archive for the ‘Stem Cell Negative’ Category

CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial – Stock Day Media

Tuesday, December 3rd, 2019

First metastatic triple-negative breast cancer patient showed no detectable circulating tumor cells (CTC) or putative metastatic tumor cells (EMTs) in the peripheral blood.

Read More...

Stem Cell Therapy May Improve Heart Health In New Ways – TheHealthMania

Tuesday, December 3rd, 2019

Recently, a new study that appears in the journal Nature, focuses on stem cell therapy and shows unexpected ways in which it may be helpful in recovering the health of the heart. Stem cell therapy has become popular in the past few years due to its benefits for a big number of health conditions

Read More...

Transfection Technologies Market Survey by Industry Trends, Growth Rate with CAGR Analysis 2026 By Top Key Players Lonza., Promega Corporation.,…

Tuesday, December 3rd, 2019

Latest Study on Industrial Growth of Transfection Technologies 2026 By-Data Bridge Market Research A detailed study accumulated to offer Latest insights about acute features of Transfection Technologies . The report contains different market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary and SWOT analysis

Read More...

REGENERATIVE MEDICINE: Stem Cell Therapy 101 | Events Calendar – Richmond.com

Tuesday, December 3rd, 2019

'; $('#bh-flyover-button-btn-787708').popover({ container: '#bh-flyover-button-btn-787708', placement: 'bottom', content: sMemberBtnHtml, trigger: 'focus', html: true, delay: { 'show': 500 } }); $('#bh-flyover-button-btn-787708').popover('show'); $.cookie('bh-flyover-ck', 'true', { path: '/', expires: 1 }); $('#main-page-container').click(function(){ $('#bh-flyover-button-btn-787708').popover('hide'); }); } } $('#bh-flyover-button-nav-787708').show(); });

Read More...

BidaskScore Ups Gamida Cell (GMDA); Shorts at Axt (AXTI) Lowered By 0.34% – The Broch Herald

Tuesday, December 3rd, 2019

In a analysts note revealed to clients and investors on Friday, 29 November, equity research analysts at BidaskScores research division upgraded Gamida Cell (NASDAQ:GMDA)s stock to a Hold. Axt Inc (NASDAQ:AXTI) had a decrease of 0.34% in short interest. AXTIs SI was 1.63M shares in December as released by FINRA.

Read More...

Syros to Present on Core Drivers of Metastasis in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium – Business Wire

Thursday, November 21st, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the company and its collaborators from the Whitehead Institute for Biomedical Research will present on the identification of core drivers of metastasis in triple-negative breast cancer (TNBC) in a poster presentation at the 2019 San Antonio Breast Cancer Symposium (SABCS), taking place December 10-14 in San Antonio, Texas.

Read More...

Incysus Therapeutics to Present at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting – Yahoo Finance

Thursday, November 21st, 2019

NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc

Read More...

Rational discovery of antimetastatic agents targeting the intrinsically disordered region of MBD2 – Science Advances

Thursday, November 21st, 2019

Abstract Although intrinsically disordered protein regions (IDPRs) are commonly engaged in promiscuous protein-protein interactions (PPIs), using them as drug targets is challenging due to their extreme structural flexibility. We report a rational discovery of inhibitors targeting an IDPR of MBD2 that undergoes disorder-to-order transition upon PPI and is critical for the regulation of the Mi-2/NuRD chromatin remodeling complex (CRC)

Read More...

End of blood donor clinics in Timmins – Timmins Press

Thursday, November 21st, 2019

Clifford LeBrun is seen here on Tuesday donating blood for the 269th time in his life. Wednesday marks the last day the Canadian Blood Services will be holding donor clinics in Timmins.Elena De Luigi/The Daily Pressjpg, TD For Clifford LeBrun, donating blood is personal. On Tuesday, he donated for the 269th time at the last Canadian Blood Services donor clinic being held in Timmins.

Read More...

Ten brands blurring boundaries in personal care and beyond – The Drum

Thursday, November 21st, 2019

They always say time changes things, but you actually have to change them yourself. Andy Warhol As the early adopter mindset filters out into mainstream thinking and behaviors, brands need no longer target their innovations towards a small group of consumers the floor is open and the consumer demand growing across all demographics for brand innovation. The boundaries of what we might have traditionally considered as personal care are shifting with brands exploring new territories and opportunities to take care of the body and mind from a more holistic perspective.

Read More...

Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected…

Thursday, November 21st, 2019

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results for one of the co-primary endpoints from CheckMate -915, a randomized Phase 3 study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo alone for the adjuvant treatment of patients who have had a complete surgical removal of stage IIIb/c/d or stage IV (no evidence of disease) melanoma. A statistically significant benefit was not reached for the co-primary endpoint of recurrence-free survival (RFS) in patients whose tumors expressed PD-L1 3 and up to 5 times the upper limit of normal (ULN), if AST/ALT is > 1 and up to 3 times ULN at baseline and increases to > 5 and up to 10 times the ULN, and if AST/ALT is > 3 and up to 5 times ULN at baseline and increases to > 8 and up to 10 times the ULN. Permanently discontinue OPDIVO and administer corticosteroids if AST or ALT increases to > 10 times the ULN or total bilirubin increases > 3 times the ULN

Read More...

European Commission Approves Two New Regimens of Merck’s KEYTRUDA (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent…

Thursday, November 21st, 2019

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Mercks anti-PD-1 therapy, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (combined positive score [CPS] 1). This approval is based on findings from the pivotal Phase 3 KEYNOTE-048 trial, in which KEYTRUDA, compared with standard treatment (cetuximab with carboplatin or cisplatin plus 5-FU), demonstrated a significant improvement in overall survival (OS) as monotherapy (HR = 0.74 [95% CI, (0.61-0.90); p=0.00133] and in combination with chemotherapy (HR=0.65 [95% CI, 0.53-0.80]; p=0.00002), in patients whose tumors expressed PD-L1 (CPS 1). This disease is especially debilitating since it can be highly visible and affect a patients appearance and their daily functions, such as eating and speaking, said Professor Kevin Harrington, investigator for KEYNOTE-048, professor of biological cancer therapies at The Institute of Cancer Research, London, and consultant clinical oncologist at The Royal Marsden NHS Foundation Trust

Read More...

After Touching 52-Week Low, Is Seneca Biopharma, Inc. (SNCA)’s Near-Term Analysis Negative? – FinanceRecorder

Monday, November 18th, 2019

The stock of Seneca Biopharma, Inc. (NASDAQ:SNCA) hit a new 52-week low and has $0.79 target or 4.00 % below todays $0.83 share price. The 7 months bearish chart indicates high risk for the $3.19 million company

Read More...

Circulating Tumor Cells (CTC) Market To Reach USD 27.80 billion by 2028 : Thermo Fisher Scientific Inc., STEMCELL Technologies Inc, SRI International,…

Monday, November 18th, 2019

The circulating tumor cell (CTC) market report analytically evaluates the most important issues that may appear on the market in relation to sales, exports / imports or imports. The circulating tumor cell (CTC) market analysis described in this report provides a mixed test of segments to witness the fastest development of predicted prediction frames

Read More...

Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program – Business Wire

Sunday, November 17th, 2019

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today provided an update on OPC1, the Companys oligodendrocyte progenitor cell (OPC) therapy currently being tested in a Phase I/IIa clinical trial, the SCiStar Study, for the treatment of acute spinal cord injury (SCI)

Read More...

Celgene Receives CHMP Positive Opinion for REVLIMID (lenalidomide) in Combination With Rituximab for the Treatment of Adult Patients With Previously…

Sunday, November 17th, 2019

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of REVLIMID (lenalidomide) in combination with rituximab (anti-CD20 antibody) (R) for the treatment of adult patients with previously treated follicular lymphoma (FL) (Grade 1-3a).

Read More...

In vitro culture of cynomolgus monkey embryos beyond early gastrulation – Science Magazine

Sunday, November 17th, 2019

Huaixiao Ma State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China.State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China.Innovation Academy for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China. Jinglei Zhai State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China.Innovation Academy for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China.Institute of Zoology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Beijing 100049, China. Haifeng Wan State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China.Innovation Academy for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China.

Read More...

Editas and Celgene sub Juno are tackling hottest immunotherapy cells – Endpoints News

Sunday, November 17th, 2019

As the first CRISPR-edited cancer patients watch their treatments unfold, one of the first CRISPR companies is rejigging a major oncology deal. Editas Medicine is amending its long-running collaboration with Celgene and their subsidiary Juno Therapeutics. The new deal will expand the focus of their work to cover a subset of immune cells that have become an increasingly hot target for immunotherapy: gamma-delta cells

Read More...

Stem Cell Banking Market Overview and Scope 2019 to 2025 | Key Players: China Cord Blood Corporation (China), CBR Systems, Inc. (US), & more -…

Sunday, November 17th, 2019

Growing Opportunities in Global Stem Cell Banking Industry 2019 The market report envelopes all-in information on the global Stem Cell Banking Market and the nature of the market growth over the foreseeable period. The report provides a comprehensive elaboration of the positives and negatives of the global Stem Cell Banking market with Regression Analysis, S.T.E.E.P.L.E and Porters Five Forces Analysis.

Read More...

Oct4, Considered Vital for Creating iPSCs, Actually Isnt Needed – The Scientist

Wednesday, November 13th, 2019

Since 2006, when Shinya Yamanaka, now the director of the Center for iPS Cell Research and Application at Kyoto University, discovered a method that could guide fully differentiated cells back to their pluripotent state, scientists have been using his recipe to produce induced pluripotent stem cells.

Read More...

Page 11234..10..»


2019 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick